Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

• Status: Completed
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the effectiveness and safety of two different doses of temsirolimus (Torisel).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Have confirmed mantle cell lymphoma diagnosis.

• Have measurable disease.

• Have received at least 2 prior treatment, which may include stem cell transplant.

• Have adequate organ and bone marrow function.

• There are other criteria--please discuss with your doctor.

Exclusion Criteria:

• Had any prior treatment with temsirolimus or mTOR inhibitor.

• Had allogeneic stem cell transplant within last 6 months and on immunosuppressive therapy.

• Has active or untreated brain or central nervous system metastases.

• There are other criteria--please discuss with your doctor.